Syros Pharmaceuticals, Inc. (NASDAQ:SYRS – Free Report) – Analysts at HC Wainwright reduced their FY2023 earnings per share estimates for Syros Pharmaceuticals in a report released on Wednesday, November 15th. HC Wainwright analyst A. Fein now expects that the company will post earnings per share of ($4.58) for the year, down from their previous estimate of ($4.00). HC Wainwright has a “Buy” rating and a $15.00 price objective on the stock. The consensus estimate for Syros Pharmaceuticals’ current full-year earnings is ($4.41) per share. HC Wainwright also issued estimates for Syros Pharmaceuticals’ Q4 2023 earnings at ($1.07) EPS, Q1 2024 earnings at ($0.91) EPS, Q2 2024 earnings at ($1.36) EPS, Q3 2024 earnings at ($1.19) EPS, Q4 2024 earnings at ($1.22) EPS, FY2024 earnings at ($4.69) EPS, FY2025 earnings at ($3.31) EPS, FY2026 earnings at ($0.03) EPS and FY2027 earnings at $5.60 EPS.
A number of other brokerages also recently issued reports on SYRS. Piper Sandler cut their price objective on shares of Syros Pharmaceuticals from $11.00 to $7.00 and set an “overweight” rating for the company in a research report on Tuesday, October 3rd. StockNews.com started coverage on Syros Pharmaceuticals in a research report on Thursday, October 5th. They issued a “hold” rating for the company. One equities research analyst has rated the stock with a hold rating and four have given a buy rating to the company’s stock. According to MarketBeat.com, Syros Pharmaceuticals currently has a consensus rating of “Moderate Buy” and a consensus price target of $12.50.
Syros Pharmaceuticals Stock Performance
Shares of NASDAQ SYRS opened at $2.98 on Friday. Syros Pharmaceuticals has a 12-month low of $2.09 and a 12-month high of $5.67. The firm has a market capitalization of $62.78 million, a price-to-earnings ratio of -0.79 and a beta of 1.46. The company has a current ratio of 4.31, a quick ratio of 5.38 and a debt-to-equity ratio of 1.09. The firm has a 50 day moving average of $3.05 and a 200 day moving average of $3.38.
Institutional Trading of Syros Pharmaceuticals
Several institutional investors and hedge funds have recently added to or reduced their stakes in the business. CHI Advisors LLC bought a new position in Syros Pharmaceuticals in the 1st quarter worth approximately $2,049,000. Two Sigma Investments LP purchased a new position in Syros Pharmaceuticals during the fourth quarter valued at $38,000. Walleye Trading LLC bought a new stake in Syros Pharmaceuticals in the 1st quarter valued at $36,000. BNP Paribas Arbitrage SA lifted its stake in Syros Pharmaceuticals by 540.4% in the 2nd quarter. BNP Paribas Arbitrage SA now owns 34,608 shares of the company’s stock worth $33,000 after purchasing an additional 29,204 shares in the last quarter. Finally, Prudential Financial Inc. bought a new position in shares of Syros Pharmaceuticals during the 2nd quarter valued at about $32,000. Institutional investors own 51.29% of the company’s stock.
Syros Pharmaceuticals Company Profile
Syros Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development of treatment for hematologic malignancies. The company's lead product candidates are Tamibarotene, a selective retinoic acid receptor alpha agonist, which is in Phase III clinical trial for genomically defined subset of patients with myelodysplastic syndrome and Phase II clinical trial for patients with acute myeloid leukemia; SY-2101, a novel oral form of arsenic trioxide for treating patients with acute promyelocytic leukemia; and SY-5609, a cyclin-dependent kinase 7 inhibitor, which is in a Phase I clinical trial in patients with select advanced solid tumors.
- Five stocks we like better than Syros Pharmaceuticals
- Low PE Growth Stocks: Unlocking Investment Opportunities
- 3 large caps with red hot RSIs with upside
- How to Evaluate a Stock Before Buying
- Johnson Controls International: Nothing but upside for investors
- Stock Market Upgrades: What Are They?
- Unity Software’s resilient rebound post-earnings setback
Receive News & Ratings for Syros Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Syros Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.